This 2 arm study will evaluate the impact on fibrosis at week 52 of an early biopsy, in patients who have received a kidney transplant from an expanded criteria donor. Patients will be randomized to one of two groups; the first group will have a biopsy at day 10, and the second group will receive standard management. All patients will be given CellCept as standard of care. The anticipated time on study treatment is 1 year, and the target sample size is 100-500 individuals.

Inclusion Criteria:

• adult patients, >=18 years of age;
• in receipt of an initial cadaveric kidney transplant;
• in receipt of graft with biopsy;
• in receipt of a 'marginal' kidney transplant.

Exclusion Criteria:

• in receipt of a second kidney transplant;
• in receipt of a multi-organ transplant or a double kidney transplant;
• malignant tumor, or a history of cancer in past 5 years, other than successfully treated basal cell or spinocellular cancer or cancer in situ of cervix;
• replicating hepatitis B and/or C, or HIV positive serology.